Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Dow
Harvard Business School
McKinsey
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,157,456

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,157,456 protect, and when does it expire?

Patent 7,157,456 protects XARELTO and is included in one NDA.

This patent has eighty-four patent family members in forty-six countries.

Summary for Patent: 7,157,456
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/181,051
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,157,456
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,157,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-004 Oct 11, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PULMONARY EMBOLISM (PE)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PULMONARY EMBOLISM (PE)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT)   Start Trial
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PULMONARY EMBOLISM (PE)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,157,456

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 62 924Dec 24, 1999
PCT Information
PCT FiledDecember 11, 2000PCT Application Number:PCT/EP00/12492
PCT Publication Date:July 05, 2001PCT Publication Number: WO01/47919

International Family Members for US Patent 7,157,456

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 032436   Start Trial
Austria 289605   Start Trial
Australia 2004218729   Start Trial
Australia 2841401   Start Trial
Australia 775126   Start Trial
Bulgaria 106825   Start Trial
Bulgaria 65683   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Johnson and Johnson
Boehringer Ingelheim
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.